Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

<p>Differences in intrinsic subtype classification from baseline to surgery in the POETIC subset and the NeoAI study. Changes of intrinsic subtype classifications in all the POETIC-treated samples (<b>A</b>); in POETIC Luminal B–treated samples (<b>B</b>); in POETIC con...

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Milana A. Bergamino (15038015) (author)
Diğer Yazarlar:	Gabriele Morani (15038018) (author), Joel Parker (15038021) (author), Eugene F. Schuster (9726535) (author), Mariana F. Leal (15038024) (author), Elena López-Knowles (15038027) (author), Holly Tovey (9360536) (author), Judith M. Bliss (8827107) (author), John F.R. Robertson (15025368) (author), Ian E. Smith (1545553) (author), Mitch Dowsett (645) (author), Maggie C.U. Cheang (14946768) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biomarkers Genetic biomarkers Breast Cancer Drug Resistance Novel mechanisms Endocrinology Translational Research
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Yazar:: Milana A. Bergamino (15038015)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
Yazar:: Lixuan Wei (14962431)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S10 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S11 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S7 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S8 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S9 from The EstroGene Database Reveals Diverse Temporal, Context-Dependent, and Bidirectional Estrogen Receptor Regulomes in Breast Cancer
Yazar:: Zheqi Li (14961021)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Yazar:: Juliana Navarro-Yepes (17079059)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Yazar:: Andrés Elía (15055031)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Yazar:: Emil Christensen (15054394)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Yazar:: Emil Christensen (15054394)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
Yazar:: Michael D. Nyquist (16918265)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figures 1-4 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
Yazar:: Michael D. Nyquist (16918265)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Yazar:: Andrew A. Davis (15030032)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Figure s2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 3 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Yazar:: Nicolas A. Giraldo (15050937)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3ajng3u03vs8igi39823pv4dgq